Asia Firmly On The Radar For Actavis/Allergan
This article was originally published in PharmAsia News
Executive Summary
For a company that took a step back from China at the beginning of this year, Actavis is again keen to stress that its $66 billion acquisition of Allergan will give it a stronger presence in Asia, including in the key markets of China and India.